Ivermectin and vaccine injury

welcome to this talk and welcome back to professor Robert clany Professor, thank you for coming back, it's a pleasure John, you are now well known on this channel, professor of pathology, professor of medicine, consulting physician for decades, published medical researcher and of course course, author and We have something really interesting today about his clinical work to discuss about Robert now, before we do this kind of Preamble, is that normally in the past people would have an article, a primary source article or at least a topic of conversation about what we are doing. We are about to discuss it because it is brand new medical information, but Robert and I no longer need to have Publications for our curriculum VII.

We're already past that stage, so we're actually bringing this D directly through this new medium and we're calling this evidence-based communication, now we're going to give some pretty surprising findings, I think really, but in a very positive way, but before doing so, we just have to emphasize that we are not prescribing any medicines, we are not carrying out any medical interventions on you or others based on what we say, but we are appealing to doctors and researchers to take care of this, so Robert, what are the particular patients that you've been seeing and what's the particular finding that John has in this particular conversation between you and me?

It came up because, in the previous talk, about a week ago, I looked at Long Co and at the end we talked about possible forms of treatment and I talked a little bit about how I've been managing the patients that I see and I just want to emphasize that you know we're not sitting here today talking about how you should treat yourself or someone like you well. What we are trying to do is identify that there are very interesting opportunities to look into the future. and uh, what we're talking about today should be picked up by those who have the opportunity to do standard randomized control trials that will be very easy to do for those people who run large clinics.

I see a limited number of patients, so I think that's really important because, after our last chat, I went to work yesterday and I got a ton of emails from really interesting nice people and I'm just not in a position where I can give those people the kind of help that they need and I wish I could so, um, it's heartbreaking, right? I mean, I'm the same. I get so many emails, but of course you are still a clinical doctor and you get emails from people saying: doctor please help me, but I am not in a position to help everyone, that's why we are appealing to all doctors, It is not like this?

Yes, it breaks your heart. a way that we can at least provide our thoughts and how things are going and start a conversation and the idea of ​​an evidence-based communication conversation came up, like probably using modern technology to communicate in a way that certainly wasn't available to me when I had all the infrastructure with secretaries and registrars and all those people around me who could take up these ideas and do something with them and we are going to talk about the use of ivantin in the post-long Covid and long Covid

vaccine

. Syndrome and I think what Robert found in his clinical experience is that people who have had post-

vaccine

lesions, even if they have a negative nucleocapsid protein or antibodies, in other words, they haven't had the virus, they have a presentation particular, so after the vaccine.

The syndrome has a particular presentation and post-Covid people who have had Covid infection have a particular presentation and there are many commonalities between these two presentations and they both seem to respond to the same type of treatment approach. Yes, I think that is a very good summary of what was discussed the other day was that there are two syndromes that have great similarities. There is the syndrome in which you receive repeated vaccines. In particular, messenger RNA vaccines where the genetic material is disseminated and then the expression of Spike is disseminated. protein in cells throughout the body and you have a very similar Sim syndrome that can occur and is much better understood and recognized, maybe not understood, but certainly recognized, which we call Long co uh, so in a sense you have long Co and post-vaccination. after infection for a long time Co and it's certainly my experience and talking to others it's um it's other people's experience that those who get post vaccination for a long time, for simplicity, many of them will continue and of course they will get Co , they will suffer an exacerbation of almost identical symptoms.

And so there's something in common with the Spike protein that seems to be involved and at the end of the talk we had the other day, I quickly went over some of the ideas that I've been treating my patients with and one of them, which I'm excited about. much as potential, was to give individuals a 4 to 6 week trial, icton, now, this is not a treatment for Co, so we are not talking about icton to treat Co. here we are talking about the use of a drug that recently It has been shown to have a high affinity for binding to the spike protein that is in the vaccine and of course to the virus because that is the attached part of the virus. enter the cells of the body and this has been done by a group in the United States and initially also with a group in France and initially it was developed as an idea and we are talking about In the last few months, three studies of which I was part of one, but a very small part, three studies showed that if patients who have low oxygen saturation are treated with this medication, the oxygen saturation increases to normal in most cases within 24 hours. which didn't make sense if you're suppressing inflammation and then it was picked up showing that if you take your red blood cells or mine or anyone's and add a little bit of Spike protein, they all clump together and this of course is doing a very inefficient transfer of oxygen from the lungs to the blood, so the saturation decreases, but if you put small amounts of this drug in the test tube, the aggregation disappears or does not occur, and there are a lot of really interesting studies that are done. put together when this concept is understood, for example, people looking at blood flow through small vessels under the tongue, have shown that in Long Co, for example, as well as in co, there is this movement of reduced perfusion use. of blood through these vessels goes to larger vessels and when you treat them it changes, so it's a very exciting concept that has solid, very solid science, and my point of view was that if this is the case, then let's try to treat patients, so I've treated a small number, maybe six eight patients, uh, and they've all had more or less similar results, um and um, you know, it raises a lot of questions, it's been fantastic in the short term, obviously, there's many questions that need to be answered.

We are asked: we need to establish the safety of long-term use of a drug that would otherwise have been extremely safe, but we don't know that people have not been treated every day for long periods of time, so these problems exist . uh there are uh the questions of how long it works for a long time the disease escapes use but in many ways it's exactly the same as the data that we got several years ago when we were looking at athletes that I was. talking about who has the Epstar bar or the glandular fever virus or the infectious modern nucleosis virus that sustains a chronic fatigue disease uh and if you treat them with an antiviral agent um a lot of them, most of them actually reversed. your level of confusion or your cognitive um wire Problems with energy activated fatigue that we talked about, so I think the possibility is that we're starting to look at mechanisms that can expand to a whole range of disorders related to chronic fatigue syndrome. which is so terrible. problem in society with so many patients and this could be one of the good things that comes out of Co they were thinking about the pathophysiological mechanisms, the disease processes, the treatment modalities that could be applied to many, not all, but yes to many, chronic fatigue syndromes, yes, this is exactly my point of view and my opinion that we learn all the time and there has been such focus and attention in Co correctly, so now we can say well, we are learning this in this context, can we generalize this to other circumstances and uh, I strongly believe that we can, so you've been treating some patients with post-vaccine injuries, uh, Robert, we now know that some of these are purely post-vaccine injuries because they have antibodies against the Spike protein in the absence of antibodies against the nucleocapsid protein, um, some of them are.

Long Covid because they have had the infection and some of them I hate to use the term, but they are hybrid syndromes, post-vaccine hybrids and long Covid syndromes, uh syn, now, um, your patients that you are seeing, we have symptoms here like pain on the chest. faint fatigue cloudy brain can you just tell us in a sense describe the suffering and clinical characteristics that these patients present to you? Well, there is some common ground. What we discussed the other day was that, for a long time, Co has been confused to some extent. because it's a heterogeneous diagnosis, it's someone who has persistent symptoms 3 months after having Co, yes, and we know that at least two components contribute to this.

The first is that you get a classic post-viral fatigue illness that is characterized by a There are several things, but the two most notable are what I call energy-activated fatigue, your ceiling is lowered in terms of what you can do if you push yourself, they get, they pay for it, they get several days of significant fatigue and illness, MH. and the second is that they have mental confusion or cognitive defects, if you want to be a little more precise, we talked about examples the other day, so, then we talked about a second set of symptoms that are due to more structural damage and I think the interesting thing What's emerging from, certainly, the observations of the patients that I'm seeing is that there may be a closer parallel to many of these symptoms, which I'm not sure of. people see the symptom, yes they can see the screen, yes they can see what I can see, okay well now what I do with my patients and some are better than others at doing this, but this is actually of a patient who is happy.

I asked him if, without obviously mentioning his name, it's a case study, isn't it? Yeah, and now this is actually the data that the patient brought to my clinic yesterday, actually, uh, and um, uh, what? What I asked them to do is take the symptoms that they're worried about and give them a scale from 0 to five, where zero would be fantastic, you know, perfectly normal help, five would be disability, can't get out of bed or, you know, so bad. as you can imagine and then offset each of them, take their symptoms and create a scale that is relevant to them and you can see this particular person, she got chest pain, she fainted, the particular person had POT syndrome, that many people would know where you are fainting all the time you have autonomic nervous system involvement, a decrease in the volume of fluids in the body and that comes along with postural hypertension, which means that you stand up, you can faint, just remind us what that means Robert um postural orthostatic uh takic cardiac tachycardia takic cardiac syndrome, right?

In other words, when you get up, your heart goes at 90 degrees, that's it, and you feel dizzy and want to fall again, dizzy and fall. so is fainting, which was a big problem with this particular patient, energy activated fatigue and what they call cloudy brain fog, which I call cognitive, um, cognitive impairment, and so, you can see that, on December 13 . were the four of five four of five five of five this particular place really quite sick weren't they extreme problems? completely unable to leave the house get up um go to university all that kind of stuff um now I think so I understood that graph, again, this is a graph that was drawn by the patient.

I drew this graph, yeah, yeah. One of the general points I would like to make is that I will make two points. The first one is that, um, the interaction. and working with the patient is part of the management team and this just shows the extraordinary value of having a relationship where the patient understands this and participates. This is not a graph that I have drawn, it is a graph of those figures that you just saw and you can see dramatic changes now what you are seeing is a group of four lines, each of those lines relates to the different symptoms that we go through in that table now um I can't remember I think I I Since that's chest pain, fainting, fatigue, cloudy brain, so those are the classic symptoms of post-viral fatigue illness plus chest pain , which does not usually occur in people with the Epstar Bar virus and I have always seen it as another form It is a structural problem and what is fascinating to me, well, a lot of fascinating things here is thatall symptoms change more or less.

You know, this is a single patient, but it's a very important observation of a single patient and what you've seen there is basically a complete one. complete remission Improvement from a person who was incapacitated to a person who was functioning fairly normally after five or six weeks of taking this particular medication now the idea was to stop the medication and see what happens and as you can see Basically there are about 10 days in which complete remission is maintained and then all the symptoms started to return, after about a couple of weeks, to where they were before, yes, now, so they started taking the i on December 13, that's right, and They finished the second one, on January 2, and you can see. and then the symptoms started when they looked again around the 7th, I think it's not January, yes, January 7th and the 10th, there are two entries and you can see that the symptoms are clearly the seventh.

That's fine, but by day 10 the symptoms start to return and as you can see, you know there's a fluctuation. This is a subjective test. What we were pointing out at the beginning was that this would be very easy for someone who has access. patients in the time and resources to do a randomized control trial to do two things, one is to solidify that this is real now. I am showing you this as a typical result of all the patients I have treated. Now, like I said, it's only six or eight people and some seem to get a fuller benefit than others, um, uh, but this is what I'm showing you because it's, uh, um, it's the best graph I would make, well, It's totally awesome, Robert.

I have horrible symptoms, really high lines, you start the ivin and you can expect it to affect one or two symptoms, but they all improve dramatically to the point where this patient basically resumed a normal life again, that's exactly right and then. A few days after stopping taking the icin, the symptoms came back again, that's right, and if you look at the symptoms, they're changing in parallel, which strongly suggests that what you're seeing is a common mechanism, yeah, and like me. He said the reason I've been doing this is the studies done by my colleagues in particular states that show this high affinity.

What they did was they used a computational approach. Four different groups did this and looked at all kinds of uh. medications available to see which one binds most closely to the spike protein and this is called in silico, many people will know what it means in vivo means a study is done on the whole animal, the whole person in vitro means it is done in a test tube now, now all these smart people have in silico studies, which means they do computer testing on me, but I'm familiar with the literature and it's very impressive, yeah, and what they measure, the actual binding affinity, yeah , and the medicine that emerged in everyone. of these, right on top of everything else, was this icon, yeah, and uh, so the same person in the United States, who I have to meet, was the one who did the test tube studies with the red combination. cells and how that was blocked by icton and then several clinics in the United States and South Africa have done the studies using oxygen saturation in people without oxygen, these were not people taking oxygen and it just didn't make sense. uh, I can remember the data from the states that I was a little familiar with.

How can reversal be achieved in these people in 24 hours? Because if you're suppressing inflammation, that's going to take days and actually if you look at other treatments. Um or another natural history of oxygen saturation reversal, you're looking at the rest of 5 7 8 days and this is happening in 24 hours. This is actually quite exciting, Robert. I'm getting excited because it's just bringing us together. all kinds of stuff, let me go over this and see if my thinking is correct here, so we have the spike protein and the mectin gums the end of the spike protein, that's basically like putting a dagger in its sheath exactly.

It's disarming, that's right and it stops two things: proteins, it stops the virus from entering the cell, so it stops the infection and it stops the uh Spike um and the virus once it's been infected, causing problems in the blood vessels. small ones, so this This and it's very important to realize that it has both benefits of linking and blocking, but the interesting thing that this shows is that what else? I can't think of any mechanism other than a blocking mechanism that creates this kind of pattern that, like I said, I've now seen in something that virtually every patient, the half dozen or so that I've treated, increases some level of benefit. and they all say that when they stop it after a few weeks or two, the symptoms will start to return.

So I guess in pharmacology we call this competitive inhibition, right? It's like binding that binding to that site and yeah, the spike protein seems to be what binds if you like red blood cells together. So now we have small groups of red blood cells. I remember the work done by Jackie Stone in Zimbabwe, yes, well, she was one of the three stones and she was working in a hospital in a poor area with no oxygen exactly. So what you did was you gave the patients ice and you had a reasonably sized cohort and the oxygen saturations improved dramatically exactly, so what would be happening there is that the spike protein was sticking all of these cells together, giving you big clumps and Capillaries passing through blood vessels pass through alvioles.

The pulmonary vasculature is very, very small, very small. Very small capillaries get blocked very easily, so by removing the glue that held these red blood cells together, they became small again and were then able to fit. through the capillaries again, that meant they could pick up the oxygen because the big clumps weren't passing through the capillaries, so he was having a profusion of pulmonary hypoemia, he wasn't getting the blood supply through his lungs exactly exactly and and and and and that just reversed it, the oxygen saturations increased within hours and I was like you. I said if these data are correct.

Can they increase so fast? But that mechanism makes a lot of sense and I've been talking to someone named Adam. I mentioned to you lately that Robert and I have his permission to talk about this, the video is coming out soon, and for months he suffered intolerable, absolutely intolerable, cramps in his legs, extreme pain, couldn't sleep, couldn't sleep for a long time. He was hallucinating for weeks from lack of sleep and that makes sense because he was producing enormous amounts of Spike protein. We know that his pathology results in enormous amounts of Spike protein and this is more than 18 months after his astrogenic vaccine. and again, those lumps in combination with the swelling of the small vessels in his legs could have resulted in what you would call intermittent claudication, he really just wasn't getting the blood supply, he was feeling this excruciating pain. weeks I haven't seen that in um well, I don't remember any of my patients speaking up, but it makes sense, but it's the same mechanism, it all fits together, right?

Certainly, several of my patients have done so. He had what's called small fiber nerve neuropathy where his legs burn terribly and now I'll be sure to ask you about the dice as well, yes, Adam had that too, but there were two different pains, there was the neurological burning. neuropathic type pain, yes, we are familiar with the treatment of neuropathic pain and there was also the cramps, the intermittent claudication type pain, so, two, two pain mechanisms, but both are ultimately explained by the spike protein which causes inflammation in the peripheral nerves or the spike protein that causes. inflammation in the small blood vessels in combination with the buildup of red blood cells, it just makes a lot of sense, yeah, what, what, what, I think what's interesting about this particular graph is that, one of the components of these fatigue diseases What we call POT syndrome is this thing of fainting, dropping blood pressure, the autonomic nervous system that has been almost refractory to almost all treatments and what I find very exciting is that the post-vaccine disease components of this particular person. it's the reversal of the pots, the postural hypertension, which I haven't seen in any of the patients over the years that I've seen with POT syndrome so dramatically, with any other particular treatment, so I really it's cementing the idea that there's an antigen that causes fatigue illnesses, uh, and if you can block or eliminate that antigen in some way, then you can get remission of symptoms, which we have as a path, you know, we have as a pathological mechanism there for hypoxia in acute covid for agglutination, I mean, do we have a pathological mechanism for pots that would make sense in the context of other diseases maybe not, I, I, you know, it was just when I saw this graph Yesterday I said, wait a second?

I know this isn't just fatigue and um and brain symptoms either, it's also the pots component that seems to be benefiting. I mean, I think you have to say that I can't think of any other mechanism and overnight I asked the question. From my colleague in the states who's been doing all this work on I-blocking, I said, can you come up with another mechanism? I got a really nice email this morning just saying oh wow, that's not that exciting, but no comment. about some alternative explanation, so I can, I can, I can, I can, I can make one up, I can make one up, and when you get over it, Robert, please, yes, I'm sure we hadn't planned this at all, this is, this is just so we know.

We know that the Spike protein causes inflammation of the peripheral nerves and this horrible burning electric shock sensation in the arms and legs. Peripheral neuropathy caused by inflammation caused by the Spike protein presumably attacks the Myin sheath, perhaps primarily because there is In cases of demyelination, the myin is the insulation around nerve cells that might be under attack. In diabetes, you can get a similar condition, you can get peripheral neuropathy, but in diabetes you can also get autonomic neuropathy because the autonomic nervous system is functioning. in the nerve fibers, the vas nerve, for example, an autonomic nerve is working on the nerve fibers in the same way, so it is quite reasonable that the Spike protein could be attacking the fibers or the myin of the autonomic nerves of the same way it attacks the myin and the F and all the fibers in the peripheral nerves only in the peripheral nerves it causes pain in the autonomic nerves could it be causing this autonomic dysregulation could it be the same mechanism is that I think it's probably like this, I'm not sure that many of the autonomic nerves actually have Mile and leaves, but certainly the mechanism of expression of the Spike protein and the body's immune system attacking that in different organs is very real and certainly a good explanation, yes, I think.

That's interesting, the parallels with diabetes are interesting, the autonomic disorder in diabetes is very interesting and I think what we're saying here is that when a spike protein is expressed in this way, it can induce two different types of immune responses. , one that leads to the classic chronic fatigue symptoms of fatigue and cognitive decline and the second, which is more structural damage to the nerves or the heart or the brain or whatever, and both are related to an immune response to a protein Spike exposed, so by blocking that Spike protein, you can potentially ameliorate the problems of both different pathways, uh, if you like, of the disease, so pathway one would be the direct toxicity effect of the Spike protein, like stick the knife in people, the second component would be the IM immune response to the spike protein, yes there can be three.

What I'm really saying is that there are two different types of immune response: there is an immune response that leads to chronic fatigue syndrome and there is an immune response that leads to damage that is structural. like damaging the nerves damaging the heart damaging other organ systems skin whatever UMX has yeah so Adam Adam who I was talking to yesterday had a muscle biopsy and he actually found complement in the muscle yeah that's interesting, No? Yes, deposited around the blood vessels and just think about what the complement could do to the myoc sites: it would just punch holes in them and it could explode.

It's horrible, horrible, I thought, well, the complement would be deposited because it would have an IGG antibody directed against the expressed Spike protein and us. know the IG antibody uh the ig3 subsets bind particularly to the the praise and the praise that's the innate immune system that's the hand grenade that explodes the uh hand grenade pin is the IGG antibody the explosion is the complement induced uh uh Amplified series of reactions that lead to inflammation and damage. I always find that the treatments are much moresatisfactory or, to put it another way, reassuring that they are correct if there is this kind of pathophysiological pharmacodynamic explanation that makes sense and what we just did.

What you've described really is a complete picture, not entirely complete, but there are certainly many mutually consistent mechanisms that could really explain this dramatic improvement in your patients, but I'm a little disappointed that it only lasted a few days without the ice, Robert. What do we do about it? Well, I'll go back to the mechanism and symptoms comment that you made because I think it's a very, very important comment. Several colleagues and I are currently finishing an article about to publish it. We think it's very important because we're talking about how Iva Meon has been a rollercoaster that when it started no one wanted to know about it and to be fair the evidence was coming together but it wasn't very clear, well not clear enough , the problem was that the discussion was about the ISM of me, uh R of me, the mechanisms that you are describing will not occur with the dose of medication that you are using now with this new one.

The concept that has emerged through blocking the um of the uh Spike has changed things because this is happening at levels that can be achieved with treatment, and then what has happened with iaon is that it suddenly went from being a drug that for any purpose, it has been constructed in the most amazing way and suddenly we now have a very clear mechanism that explains exactly the point you are making and that correlates with the symptomatology of infection and esia through the small vessels who are not oxygenated etc., that was very, very important and of course there has been a progressive and exciting accumulation of clinical data, so now a much stronger argument can be made and this is the point of the article because I want it to be published in a Mainline Journal so doctors can start asking questions, just like this data, which is just data from a few patients, is not telling you to go out and treat everyone this way, but hey, here is some evidence, some data. that makes sense in the context of what we understand and maybe has an important role to play, but we want people to now pick it up and do the proper testing because we don't know the point that you raised, the last point that you raised is very important. . that we don't know how long it works if you're blocking it, it may be perfectly fine to give people I I and what I'm doing is titrating in these patients to get to the smallest amount of Icon given. at least frequently because we know that Icon has a very long half-life in the body over a considerable period of time, and we know that people who use the drug prophylactically will take it once a week for a long period of time, so we need to consolidate those security issues and uh uh and um and work out the dynamics so yeah we have a way to go so hopefully you'll come you might get to a situation that we don't know about but it would be nice Yes You could take 3 milligrams of ice once a week and that could be enough to keep the symptoms at bay that we don't know well yet.

I hope that in a couple of months I can control it at least with the people I know. I'm struggling because now they're cutting back to hydration. You know, what I'm doing is saying, "Okay, take it every other day for a week or two." We know that if he is going to recover, he will. within 2 weeks, if everything is fine, take it every third day, fourth day and the idea is to get to a dose that people are comfortable with, long term. Why while monitoring for any possible side effects? Actually, I'm an optimist. I'll be able to reduce the dose because of the high affinity of the spike protein, so you give it a little bit of itin and it gets close to the spike protein, yes, and that's a very good point.

I have to go back to my colleagues in the United States and they say, we know about Affinity, what is the duration, what is the duration of Bing, good point, but the problem is that people will probably have to continue giving them on a regular basis because the ice is blocking the spout. protein I mean, are we optimistic that icin could have some intracellular effect to reduce Spike protein production or is that too much to ask for? I think this goes back to the early days of 2021, when several sites and this is the The big advantage of these uh Pro um type protective substances that come from biological sources is that they are there to complete completely natural bacterial products, that's right, they are there to protect the microbe or the plant and what they do is they make the cell unpopular so that the virus replicates by reaching many different sites and those who criticized ion said: well, you know what dose you need and it really became in a sort of Bunfight when it was just when this new data came out, people said, well, you know the whole feda, but we shouldn't forget that the drug has these sites where it stops the generation of cytopathic cytotypes, uh, it stops the various pathways, uh. which are highly productive at dealing damage in different ways um yeah, I'm not sure this is playing a role right now due to the immediacy of the effect, the dependence on the icton being present and the bouncing and blocking logic. spike protein uh expression if I were one of your patients, Robert, to tell you the truth, I wouldn't give a damn about all that, all I would know is that you have given me my life back just because you are an Independent Doctor who is prepared to test a new treatment, but it is based on decades of experience based on the knowledge that it is a very safe medicine.

Yes, I think this gets to a point that is very close to my heart and what broke my heart. uh, when in my country, when uh, the disease came in the early 19s, uh, yes, 2020, 2020, 2020, I have to correct my centuries, oh, I have that problem all the time, I couldn't use, I couldn't use a drug that had been using it for 50 years, I won't mention its name, you will never publish it now, what works, what works, no, I think today we can say hydroxychloro, well, same thing, we have a new mechanism for hydroxychloroquine , uh, I guess.

To me, it's a fantastic drug, there's a drug, a drug that, as one of Australia's most experienced doctors, honestly, you've been prescribing that for 50 years and then someone tells me that in some government office somewhere they come and He says no, no. doctor, I know better, 50 years of experience Q, you know, it's just incredible the sheer arrogance of people who have no medical training and those who do have medical training sit on committees all day and have no idea and it's like If it was like me on a flight bursting into the cockpit telling the pilot no, no, no, you press that, but then you do that and then you pull the stick like that, believe me, I know these things because I don't know anything, yeah, I mean, it's Madness, let's be careful, let's not get carried away because there are some crazy people out there who do crazy things, uh, what I'm saying is that, um, yes, and we already made it clear the other day, that I am an immunologist, uh, and I see the mechanism as seas and that is why I am trying to design in each patient something different and each patient requires a different approach, so constantly clinical immunologists look at what is going wrong in this patient as a process and how can we change that? for the betterment of the patient now?

No one has done no one has done a randomized control trial that cost 50 million pounds or dollars to prove that no one will ever do it because these drugs are repeat drugs, they don't exist anymore. one is making money off of them, um, I do the same thing too, uh, and that's why the big pharmaceutical companies hate, they hate people like me, they probably also hate people like you, John and um, I think we're both in a list somewhere, Robert, well known. I'm quite surprised, but maybe they think I'm too old or something, but the bottom line is that experienced doctors use repurposed medicines every day, trying to make a difference to people suffering from a range of diseases for which classic medications don't help um now uh these repurposed medications that come from plant and biological sources uh have been around for billions of years uh we know more or less their safety profile we know what they do and how they work uh and uh I've been using hydroxy CL.

I think I pointed out in something I wrote recently that I discovered I had written about 25,000 recipes and I don't have an entry in the competition. I don't even have I know who does it, um, 25,000 and a lot of these people are people that, well, I can give you a test. I remember seeing a couple of patients who had a condition called psychosis and they weren't going anywhere because we were using all these cytotoxics. and things and I said, well, look at this, I think it's the process, um, let's see what happens with hydroxychloric and both patients had significant improvement and about a year later an article came out from a pediatrician saying, hey, I'm using hydroxy , look.

This is my I've done a series of these uh and it makes sense so um this is the way the medications should be done, but you know there's a compulsion on you to ensure that you're monitoring the safety, you're monitoring the mechanism uh and and Don't get carried away, don't use this as a general approach to things, um, that's certainly the way I've practiced medicine for all of my 50 years of work. I mean, talking is more than sober scientists at this point. What we have just done is postulate a hypothesis and a hypothesis is a testable statement that could be tested and in our opinion of course should be tested and it is up to clinicians and perhaps university departments around the world to take this on and start to try it on your own patients using your own clinical judgment.

Well, the reason you say John is so important is that he goes to any of these. Large hospitals now have long clinics with long lists of people in them. people can't understand them. I hear stories from all kinds of sources about but when you go to the clinic, what do they do right now, basically nothing, they say you know, 30, 40% of you, the symptoms will go away. in the next 12 months, maybe a few more, but 30% will still have those symptoms, you know, I'm talking to a couple of people right now about other ways that maybe we can change.

I think the microbiome in the gut is coming up, uh, as part of a connecting system, very exciting kind of work, uh, what can we do to change those outcomes? So we've talked about a system that makes sense, comes directly from science, uh, and um, as a result of a patient relationship patient doctor relationship um we're being able to work on a system uh that seems exciting I mean, we said that this it would be a short video Robert but I have one more question g g g given that idea, do you think there's a role for your um oral um or attenuated oral bacterial.

I'm not using the term vaccine, but I don't want to get into it too much today, but we talked once. I've spent many years looking at ways that you can adjust the way your airway mucosa handles a virus that you breathe in and you come up with the idea of ​​what we call immune resilience and the very simple question is do 100 people get Co 97? , 98 of those people will do very well. Well, one or two will go to the hospital and one might even die, so, these people, if you look at them, they all look the same, they say.

I mean, obviously, we know that there are predisposing factors that make people worse. But a lot of these people seem exactly the same what's the difference and the main difference is the way that virus is handled uh and you now there are ways that we can change the resilience so we can change the risk if you want , eliminate someone's risk by moving their resilience, their ability to manage in the first instance their mucosal immune response by making the delivery of tea cells remember that the respiratory tract gets its immunity from the intestine, the intestine has little things called P patches that we talked about that deliver uh these T cells and these T cells uh underpin immunity and in some people about 25% of people don't do it very well and you can make that work better by feeding more stimuli that are part of the microbiome. that is swallowed all the time so that the swallowing process works better.

It goes back to the early days. I can remember when I was doing a semester as a registrar in respiratory medicine and there was a big discussion about whether you should say it. people who have chronic lung disease with a lot of sputum should swallow it or spit it out and uh I think now that we know that you swallow it, it takes away the lesson from you, yeah, I mean, of course, if that had happened before, it would have been reduced the severity of the initial covid infection and that could reduce the likelihood of long covid.

It wouldn't work against vaccines, of course not, it's a different system, yeah, and we want, of course, I mean, I guess we still want to optimize vitamin D and things like that absolutely absolutely there's no there's no single answer uh vitamin D uh a lot of work has been done on thelast few years really um You and I, John, can remember that if you don't have enough vitamin D, you suffer from rickets or osteomalacia if you're an adult, uh, that's gone a little more than okay, it's still there, but some things were added to it. . Excellent video, by the way, by Dr.

David Rhymes on this same channel the other week. Look at it, it's fantastic, yes, absolutely great stuff. Yes, Robert, sorry, this is the last question I just thought of. Is there a role for hydroxychlorine and zinc in Long Co? Because I was thinking that if the spike protein is produced in the cell, you get more zinc in the cell we know that zinc is antiviral hydroxychloroquine will channel zinc into the cell is there a possible role for those two in combination? I do not know the answer. I can tell you what I've done. There may be uh, there may be in Co post viral long because these people presumably have virus replication, um, if they have any role in the post vaccine variant of Long Co.

I don't know what it was when I started, uh, a few months ago, um . After I got several of these patients, I started treating them with hydroxychloroquine and icton, but then I, well, at that time the story of the Ivon blockade came out, and it was very persuasive, and so what? What I've done now it's basically stop hydroxychlorine and stick with the single icon so I don't know the answer uh I understand the logic um and um you know now there's a big project for someone to do it oh there are Ph.D. and MDS coming out of this video uh by dozen robots.

I completely agree with you about having to study one variable at a time, that is, the victim is much simpler than having several variables, all in I agree and when yes, when when I started to see myself, it breaks your heart to see these places. I know some of them watch your channel so I hope not. I'm certainly not referring to anyone specifically. In fact, most of those who come to me come through your channel, which is me. I had to send a nice email saying I just can't face it because I do so many other things, but we need all the doctors and nurse practitioners and all the people around the world to step up. plate here, right? and let's start treating these patients well, they are very, very intelligent people and they follow the story, they follow your channel, they follow the story, a patient that I am sure will be watching and she is not. he or she won't care, men, um had that Pro, they decided that icton would be something to treat and you can get the cream pretty easily for Ros, which is transdermal, yeah, and they started using, they worked out how much cream to use. he was put on it to get a certain dose which actually turned out to be a pretty similar dose to what I'm giving him orally and this person had been in hospitals had been in the hospital no one had terrible neuropathies and now he's coping pretty well No I will use nothing but her cream because she is pretty convinced it works now.

I'm not suggesting this is the way to go by any means, but I'm just saying that patients are smart, and intelligent. I always work on what I always say. my patients are smarter than me and I mean that um and um she has worked to individualize and optimize her own self care that is absolutely because the doctors hadn't found anything to help yeah so if you've had experiences similar let us know in the comments because Robert and I were talking about this. Feedback is really important because it is a form of qualitative research. Yes, what we found when reading the comments is that common themes emerge and, if someone wants to do a project. in the comments are in the public domain.

It would be wonderful if someone did a qualitative analysis on that, but we really need nurses, doctors, and pharmacists around the world to step up and realize that we've hypothesized that this is a treatable condition uh, just saying. Two things about it, please, we live in a different world, technologies are changing, you know, the randomized control trial has been postponed as something very expensive, expensive, done by big guys. Pharmaceutical companies record great things, but they are flawed, as we well know, and a variety of forms have emerged that have validity in terms of producing evidence and John and I were talking about waiting for a second look at the data that is emerging.

I took a quick look at some of the comments from our last chat and was impressed by the number of people having similar problems. You know, we think something is quite rare because we see two or three cases, but then Look people, it reminds me of a condition, John, if you had a second, yes, of course, there is a condition in women called Volvo Volvo vaginal candidiasis. Now these are women who suffer from thrush six or more times a year. I thought it was a rare disease. because I talked to my gynecologist colleagues and I was interested because I felt that there was a way to treat this and no one at that time understood why they had it, but these women always get yeast infections the week before their period and that says and we knew that the tea cells in the blood do not pass to the vaginal and cervical mucosa very efficiently in that last period the hormonal changes block the exit of the tea cells and the hormonal changes change the consistency of the mucus exactly, so I said, well, maybe There may be a reduction in the number, so this creates a clinical problem when they can't reach the tissues where they are needed, but my point is this.

I thought, well, I won't do any research on this because my gynecologist friends tell me that this It's strange, they never see it well, the bottom line is that they don't see it because they weren't doing anything to help these patients and you talk to the general practitioners and they say, oh, I have a lot of these patients and it turns out that something like 5 %, 5% of women have Volvo vaginal yeast infections and have six or more. 5%, one in 12 women, have six. or more bouts of thrush a year, uh, and we looked and discovered that this was exactly what happened, that the tea cells in this particular group genetically had a lower reserve of the correct type of tea cells to enter the tissues. , uh and You know, we came up with several ways that we could increase that number of te-cells, so I think the point is that the primary care doctor is the person who really has an idea of ​​how important and how common the issues. so that we, the people who work in an Ivy Tower, can see what the patient and the doctor feel, maybe we can contribute and what Co has done, um, and what postco has done is that it's forced, if you like them these people, because there has been nothing, nothing to help them, so they are showing up in large numbers in clinics potentially like mine, although I see very few patients these days, but the message is to take this information to your own doctor and optimize the attention with your own doctor and now. now in Australia for example where prescribing ions is allowed, yes I would be hopeful and the situation in the states is probably more promising depending on the state, the situation in the UK doctors remains.

I don't think you'll get a I think you'd struggle to find a doctor to prescribe iect in the UK but the point is this has to change because we need to help our patients in the same way as in the UK it's legal but The doctor has been narratively brainwashed, yes. um, many, many people have told me that they asked their doctor to prescribe them ivic, the doctors refused and the same thing will happen in this country, yes, which is that you know yes, yes, yes, yes, there is very little risk and there is a potential massive benefit risk benefit analysis, you know, it's kind of basic, yes, and it's really disappointing, but it will change because eventually the obvious thing is that our hypothesis is based on multiple cases, of course, it can be rejected, in which case we will accept it. that and going back to the drawing board, but we don't think it's something unique that you can't re re we don't know, we don't really believe it, but it's a hypothesis if it's tested and it's complete. if it is corroborated in multiple instances then the authorities can only deny the truth for a while eventually the same thing they did with the helicobactor the same thing they did with theide the same thing they did with tobacco the same thing they did with the spos the same thing they did with the infected blood scandal, the same thing they did with the postal workers in my country, eventually they will have to admit it, yes, and the patients will be helped and we are very sorry for the delay, well, thank you very much.

Very much so, John, I think what I'm sure your viewers appreciate is that you're providing a kind of new and exciting platform for asking questions and the idea of ​​evidence-based communication, which your programs are based on. I think they are exciting and interesting, it will be very interesting to see where they go, because wouldn't it be wonderful if someone said, hey, I'm going to do a PhD on analyzing data that I get from the comments that follow evidence-based discussions and could do, there's enough, there's enough material there and yes, we could have a lot of material, we could solve triangulations and all kinds of mind-blowing things with it, but what amazes me is that the world's leading doctors choose to come and talk to me.

I just find it humiliating and fantastic, really, it's incredible, very well, I can tell you why it's very simple that you are the only one um, a medium who bases everything you do on evidence, yes, and that's the difference, yes, Thanks for that, Robert, yes, that's it. Well, we'll keep trying to do it, but for now, Professor Clany, as always, amazing ideas. Thank you very much for coming. It's a great pleasure.